PCM
GH icon

Prelude Capital Management’s Guardant Health GH Stock Holding History

Prelude Capital Management’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
1,421
-15,215
-91% -$1.65M 0.02% 953
2026
Q1 		$1.54M Sell
16,636
-9,914
-37% -$995K 0.12% 209
2025
Q4 		$2.71M Sell
26,550
-942
-3% -$84.3K 0.2% 111
2025
Q3 		$1.72M Buy
27,492
+2,476
+10% +$135K 0.13% 189
2025
Q2 		$1.3M Buy
25,016
+7
+0% +$313 0.13% 199
2025
Q1 		$1.07M Sell
25,009
-17,191
-41% -$742K 0.08% 296
2024
Q4 		$1.29M Buy
42,200
+24,100
+133% +$678K 0.08% 306
2024
Q3 		$415K Sell
18,100
-1,613
-8% -$45.7K 0.03% 704
2024
Q2 		$569K Sell
19,713
-4,103
-17% -$95.5K 0.04% 487
2024
Q1 		$491K Buy
+23,816
New +$511K 0.03% 640
2023
Q4 		– Sell
-8,600
Closed -$255K – 1198
2023
Q3 		$255K Buy
+8,600
New +$302K 0.02% 761
2023
Q1 		– Sell
-9,967
Closed -$271K – 1292
2022
Q4 		$271K Sell
9,967
-4,739
-32% -$217K 0.01% 829
2022
Q3 		$792K Sell
14,706
-1,237
-8% -$63.5K 0.03% 487
2022
Q2 		$643K Buy
+15,943
New +$790K 0.02% 686
2022
Q1 		– Sell
-5,226
Closed -$523K – 1978
2021
Q4 		$523K Buy
5,226
+1,656
+46% +$171K 0.01% 975
2021
Q3 		$446K Sell
3,570
-3,351
-48% -$398K 0.01% 951
2021
Q2 		$860K Buy
6,921
+4,711
+213% +$634K 0.03% 696
2021
Q1 		$337K Sell
2,210
-4,608
-68% -$696K 0.01% 1087
2020
Q4 		$879K Buy
6,818
+1,098
+19% +$126K 0.02% 513
2020
Q3 		$639K Buy
5,720
+2,070
+57% +$189K 0.03% 375
2020
Q2 		$296K Buy
3,650
+2,936
+411% +$237K 0.02% 625
2020
Q1 		$50K Buy
+714
New +$54.8K ﹤0.01% 755
2019
Q4 		– Sell
-11
Closed -$1K – 2034
2019
Q3 		$1K Sell
11
-1,389
-99% -$122K ﹤0.01% 1637
2019
Q2 		$121K Sell
1,400
-2,089
-60% -$160K 0.01% 885
2019
Q1 		$268K Sell
3,489
-5,555
-61% -$308K 0.02% 627
2018
Q4 		$340K Buy
+9,044
New +$333K 0.02% 581

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Prelude Capital Management's GH Position: Q2 2026 in Review

Prelude Capital Management reduced its Guardant Health (GH) stake by 91% in Q2 2026, selling an estimated $1.65M and leaving 1,421 shares worth $213K. The position accounts for 0.02% of the portfolio, ranked #953.

Prelude Capital Management first reported a position in GH in Q4 2018 and has held it in 26 quarters since. The position peaked at $2.71M in Q4 2025. 600 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Prelude Capital Management held 1,421 shares of Guardant Health worth $213K as of Q2 2026.
  • Prelude Capital Management sold 15,215 Guardant Health shares in Q2 2026, an estimated $1.65M.
  • Guardant Health made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #953 holding.
  • Prelude Capital Management first reported a position in Guardant Health in Q4 2018 and has held it in 26 quarters since.
  • Prelude Capital Management's Guardant Health position peaked at $2.71M in Q4 2025.
  • 600 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.